TMCnet News
Tactile Medical Announces Secondary Offering of Common StockMINNEAPOLIS, Sept. 12, 2017 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical” or the “Company”) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that certain of its stockholders intend to offer and sell, collectively, 2,750,000 shares of Tactile Medical common stock in an underwritten offering, subject to market and other conditions. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. In connection with the offering, the selling stockholders intend to grant the underwriters an option to purchase up to an additional 412,500 shares. Tactile Medical will not receive any proceeds from the offering. William Blair & Company, L.L.C. and Piper Jaffray & Co. are acting as joint book-running managers, and Guggenheim Securities, LLC is acting as joint passive bookrunner in the offering. Canaccord Genuity Inc. is acting as co-manager. The shares of common stock described above are being offered by the selling stockholders pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-220132) that was declared effective by the Securities and Exchange Commission (“SEC”) on August 31, 2017. The shares may only be offered by means of a prospectus. A preliminary prospectus supplement and accompanying base prospectus related to the offering will be filed with the SEC on or about September 12, 2017. The final prospectus supplement and accompanying base prospectus relating to and describing the final terms of the offering will be filed with the SEC and, when available, may be obtained by visiting the SEC’s website located at www.sec.gov, from William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by telephone at (800) 621-0687, or by email at [email protected], or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at (800) 747-3924, or by email at [email protected]. Before you invest, you should read the prospectus supplement and accompanying base prospectus in the registration statement and other documents incorporated by reference therein for more complete information about the Company and the offering. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Tactile Medical Legal Notice Regarding Forward-Looking Statements: Investor Inquiries: Mike Piccinino, CFA Managing Director Westwicke Partners 443-213-0500 [email protected] |